• Represented numerous life sciences companies facing securities litigation and derivative litigation following the Food and Drug Administration's rejection of new drug applications; obtained outright dismissal of majority of complaints on motions to dismiss. 
    • Successfully litigated a large number of derivative and class actions challenging M&A litigation through the country, including successful enforcement of a forum selection clause through use of anti-suit injunction in Delaware Chancery Court. Convinced Michigan Court of Appeals and Illinois Court of Appeals to affirm dismissals of merger related litigation following oral arguments. 
    • Obtained dismissal of fraud claims against former CFO of large shipping company, successfully litigated related securities fraud claims and SEC investigation. 
    • Defeated securities fraud claims against former CEO of large grocery store chain
    • Obtained dismissal of a derivative action pending in federal court against a prominent credit card company based on alleged improper marketing practices. 
    • Obtained dismissal of derivative claims against special litigation committee of large oil and gas company
    • Successfully defeated derivative action alleging breaches of fiduciary duty brought against former chair of an audit committee.
    • Obtained dismissal of fraud and misrepresentation claims against large manufacturer pending in New York state court.
    • Successfully represented prominent chemical company in highly contested securities fraud litigation and employed strategic electronic discovery tactics to streamline discovery process.  
    • In conjunction with LAMBDA Legal, provided pro bono representation for individuals seeking to retroactively enforce effect of Obergefell decision on social security benefits. Reached favorable settlement.  
    • Represent numerous pro bono clients seeking compassionate release from federal prison as a result of risks posed by COVID-19 and underlying health conditions. 
    • Securities & Derivative Litigation: Quarterly 3 2022 Update, OnPoint, October, 2022
    • Securities & Derivative Litigation: Quarterly Update, OnPoint, August, 2022
    • Securities & Derivative Litigation: Quarterly Update, OnPoint, May, 2022
    • Developments in Securities Fraud Class Actions Against U.S. Life Sciences Companies, Dechert Survey, March, 2022
    • Developments in U.S. Securities Fraud Class Action Lawsuits Against Non-U.S. Issuers - 2021 Summary, Dechert Report, February, 2022
    • Securities & Derivative Litigation: Quarterly Update, OnPoint, February, 2022
    • Delaware Court of Chancery Issues First Decision Addressing Directors’ Fiduciary Duties in a DeSPAC Merger, OnPoint, January, 2022
    • Recent Trends in US Securities and Derivative Litigation — Financier Worldwide (June 1, 2021)
    • 2020 Developments in Securities Fraud Class Actions Against Non-U.S. Issuers — Harvard Law School Forum on Corporate Governance (March 23, 2021)
    • Mitigating Risk Amid Layoff-Driven Confidential Witness Boom — LAW360 (March 10, 2021)
    • Non-U.S. Issuers Targeted in Securities Class Action Lawsuits Filed in US, Harvard Law School Forum, March 29, 2020
    • Global Securities Litigation Trends, Harvard Law School Forum, July 29, 2019
    • Recent Trends in Off-Shore Targeted US Class Actions, Harvard Law School Forum, April 30, 2019
    • INSIGHT: Life Sciences Companies Targeted in Securities Class Actions, Bloomberg, March 7, 2019
    • A New Era In Global Securities Litigation, Law 360, Feb. 16, 2018
    • Guard Attorney-Client Privilege When Sharing Legal Advice, Law 360, October 5, 2017
    • The Devil Is in the Details: A Litigator’s 5 Tips for Drafting Board Minutes, Corporate Counsel, Jan 26, 2017 
    • Delaware Courts Update: Supreme Court Issues Decision on Exculpatory Clauses, Wall Street Lawyer, June 2015
    • Recent Litigation Trends Impacting Private and Public Companies – ACC Philadelphia (March 15, 2022)
    • The Rise of Special Purpose Acquisition Companies (SPACs): How to Minimize Securities Litigation – The Knowledge Group Webinar (August 6, 2021)
    • The Ever Shifting Landscape of Special Purpose Acquisition Companies (SPAC) – ACC NY Webinar (April 27, 2021) 
    • SPAC Roundtable – Dechert LLP, Webinar (April 21, 2021)
    • Recent Developments: Securities Fraud Actions Against Life Sciences Companies - Webinar (March 4, 2021)
    • COVID-19 Coronavirus Business Impact: Securities Litigation, SEC Guidance and Strategies to Minimize Risk – Webinar (May 28, 2020)
    • Risk Management and Recent Trends in Securities Fraud Litigation Against Life Sciences Companies - Webinar (April 17, 2019)
    • Securities Fraud Litigation Against Life Sciences Companies - Recent Trends - Webinar (June 15, 2018)
    • Developments in Securities Fraud Class Actions Against US Life Sciences Companies -  Webinar (May 11, 2017)
    • From the Boardroom to the Courtroom - A Price Worth Paying? - Omaha, NE (March 22, 2017)
    • From the Boardroom to the Courtroom - "A Price Worth Paying?" - Louisville, KY (May 19, 2016)
    • Class Actions Face Challenges At the Supreme Court - Chicago, IL (March 24, 2016)
    • Co-founder and Advisory Committee Member, Women in Securities Litigation Network
    • Chicago Bar Association
    • American Bar Association